FINGOLIMOD HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Fingolimod Hydrochloride patents expire, and what generic alternatives are available?
Fingolimod Hydrochloride is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, and Zydus Pharms. and is included in eighteen NDAs.
The generic ingredient in FINGOLIMOD HYDROCHLORIDE is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fingolimod Hydrochloride
A generic version of FINGOLIMOD HYDROCHLORIDE was approved as fingolimod hydrochloride by BIOCON LTD on December 4th, 2019.
Summary for FINGOLIMOD HYDROCHLORIDE
Recent Clinical Trials for FINGOLIMOD HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Methodist Hospital Research Institute | Phase 2 |
General Hospital of Shenyang Military Region | Phase 4 |
Hoffmann-La Roche | Phase 3 |
Pharmacology for FINGOLIMOD HYDROCHLORIDE
Drug Class | Sphingosine 1-phosphate Receptor Modulator |
Mechanism of Action | Sphingosine 1-Phosphate Receptor Modulators |
Medical Subject Heading (MeSH) Categories for FINGOLIMOD HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for FINGOLIMOD HYDROCHLORIDE
Paragraph IV (Patent) Challenges for FINGOLIMOD HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
GILENYA | Capsules | fingolimod hydrochloride | 0.25 mg | 022527 | 1 | 2018-07-19 |
GILENYA | Capsules | fingolimod hydrochloride | 0.5 mg | 022527 | 19 | 2014-09-22 |